AQST - Aquestive Therapeutics, Inc.
IEX Last Trade
3.525
-1.410 -40.000%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:25 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$4.94
-1.41
-28.57%
Fundamental analysis
44%
Profitability
41%
Dept financing
37%
Liquidity
75%
Performance
40%
Performance
5 Days
-3.56%
1 Month
-26.82%
3 Months
-27.57%
6 Months
52.38%
1 Year
76.00%
2 Year
278.49%
Key data
Stock price
$3.52
DAY RANGE
$3.64 - $4.94
52 WEEK RANGE
$2.05 - $6.23
52 WEEK CHANGE
$75.12
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Daniel Barber
Region: US
Website: aquestive.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aquestive.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Aquestive Therapeutics, Inc. focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formant of buprenorphine and naloxone for the. treatment of opioid dependence.
Recent news